Anumigilimab

安米利单抗

Report date: 2026/05/13 20:02:10

Base Information

Drug NameAnumigilimab
Drug Alias NameCSL-324CSL324 G-CSFRCSL-324-G-CSFR
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Colony stimulating factor 3 receptor
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaPalmoplantar pustulosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMuriGen TherapeuticsZenyth Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring
Inactive CompaniesN/A
Active IndicationsCommunity Acquired PneumoniaPalmoplantar pustulosisAnemia, Sickle Cell +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A